

## CHAPTER II

### ANATOMY

The greater part of the pancreas in man lies in the  
**Indicazioni, limiti ed incognite  
della**

To expose the organ from the front the stomach must  
be detached. The stomach is then turned upwards.  
It is then seen as a long, pinkish, cream-coloured  
gland, stretching transversely across the posterior abdom-  
inal wall, from the lower and inner border of the spleen to the  
lower and inner border of the spleen. In the fresh condi-  
tion it has a lobulated appearance. In length it varies from 5 to 6 inches (12 to  
15 cm.). Its average weight ranges from 2.25 to 3.5  
ounces (66 to 102 grams). The general shape of the gland  
is a long, narrow, flattened band, which, according to  
"Text-book of Anatomy," is placed on its  
side, the loop being thickened to represent the head,  
the thickened stem corresponding to the body, and the  
narrow bend joining the two indicating the neck.

**CHIRURGIA  
COMPLESSA  
dei tumori del distretto  
EPATOBILIARE  
&  
PANCREATICO**

The head of the pancreas extends down-  
wards and to the left, lying in the concavity of the duode-  
num in contact with its second and third parts, and oppo-  
site to the second and, upper part of, the third lumbar  
vertebra. The short and comparatively narrow portion  
of the gland termed the neck arises from the upper  
and right part of the head. It runs upwards and to  
the left, and, after a distance of about an inch, merges  
into the "body." This, which is the longest section of  
the gland, runs backwards and to the left at the level of





Fig. 10.—Relations of the pancreas (Sobotta and McMurrich).

a cura di  
**Giancarlo Pansini**



”Devo anche calcolare cosa succede se non facciamo niente. Il chirurgo mi assicura che peggiorerà in brevissimo tempo. Però io non voglio fargli subire un’operazione senza un valido motivo.”

*P. Roth*

1991, Patrimonio. Una storia vera

Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20-year multicenter experience.

*F. Mirici-Cappa, for the Italian Liver Cancer Group, GUT | 2010 | 59:387*

## What are the key points?

Retrospective multicentre cohort study (614 elderly + 1104 younger unselected patients)

Elderly patients are more frequently treated with percutaneous ablation  
Elderly patients are less frequently treated with liver resection or TACE


**The life expectancy is unaffected by age  $\geq 70$  years**

**Patient survival is unaffected by age in each treatment subgroup**

Cancer stage predicts patient outcome in all therapeutic subsets

**Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20-year multicenter experience.**

**F. Mirici-Cappa, for the Italian Liver Cancer Group, GUT | 2010 | 59:387**




Patients at risk:

Months	0	12	24	36	48	60	72	84	96	108	120
Elderly	614	394	245	147	74	33	18	13	6	4	2
Younger	1104	737	491	307	182	104	63	35	22	10	8

**Figure 1 . Overall survival of unselected elderly and younger patients**

**Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20-year multicenter experience.**

***F. Mirici-Cappa, for the Italian Liver Cancer Group, GUT | 2010 | 59:387***



Patients at risk:

Months	0	12	24	36	48	60	72	84	96	108	120
Elderly	43	39	28	15	10	6	6	5	1	1	1
Younger	142	125	98	76	42	24	18	12	9	4	3

Months	0	12	24	36	48	60	72	84	96	108
Elderly	32	29	21	12	9	5	5	5	1	0
Younger	32	28	23	19	6	5	5	2	1	0

**Figure 2.** Overall survival of elderly and younger patients treated with hepatic resection before (A) and after (B) matching with the propensity analysis.

## Innovations and breakthroughs

Based on this meta-analysis, **elderly patients with hepatocellular carcinoma have similar outcomes compared to non-elderly patients**. Specifically, they have similar 3-year survival after resection and ablation and an improved 3-year survival after TACE, compared to non-elderly patients. **At 5-year, elderly patients had a lower survival after ablation but similar survival with resection** and TACE as compared to younger patients. Heterogeneity of patient populations and selection bias can explain some of these findings.

## Applications

The findings from this meta-analysis can be used to guide the treatment approach of elderly patients with hepatocellular carcinoma. The analysis included clinical outcomes of locoregional therapies including surgical resection, chemoembolization, and radiofrequency ablation. **Overall, elderly patients have good success with these treatments and should be considered for all treatments after assessment of their clinical status and cancer burden.**

Effects of age on survival in patients undergoing resection of hepatocellular carcinoma. *A. Cucchetti*, British J Surg | 2016 | 103:93-99

## Results & implications for *Clinical Practice*

Consecutive 919 patients with liver cirrhosis and HCC who underwent hepatectomy were divided into age quartiles for analysis. **Postoperative mortality rates were similar** between age quartiles, as were survival rates up to 3 years. A statistically significant reduction in 5–10-year survival rates was observed with ageing. Although survival after liver resection for HCC is shortest in elderly patients, **hepatic resection in the elderly can provide a survival benefit at reasonable costs.** The elderly candidates for surgery are selected carefully.



“Però io non voglio fargli subire un’operazione **senza un valido motivo**. Sarebbe una fatica del diavolo riprendersi da un intervento come questo a quarant’anni; ad ottanta, è impensabile, no? Operare sarebbe l’inizio di un orrorre, e **non operare l’inizio di un orrore diverso.**”

*P. Roth*

1991, Patrimonio. Una storia vera

Management and Outcome of Colorectal Cancer Liver Metastases in Elderly Patients: a Population-based Study. *C.M, Booth, JAMA | Oncol 2015 | 1(8):1111-1119*

## Conclusions and Relevance

Current demographics trends will lead to an increasing number of elderly patients presenting with potentially resectable CRLM. Resection of CRCLM is associated with **greater risk of postoperative mortality** among elderly patients despite less aggressive treatment. Although the long-term outcome are inferior to younger patients, a substantial proportion of **elderly patients will have long term survival** (28% to 35%).


**Management and Outcome of Colorectal Cancer Liver Metastases in Elderly Patients: a Population-based Study. C.M, Booth, JAMA | Oncol 2015 | 1(8):1111-1119**

**Table 2. Short- and Long-term Outcomes for All Patients**


Characteristic	All Patients (n = 1310)	Patient Age, y			P Value <sup>a</sup>
		<65 (n = 710)	65-74 (n = 414)	≥75 (n = 186)	
Short-term outcomes, No. (%)					
Median LOS	7	7	8	9	<.001
30-Day mortality	29 (2)	8 (1)	12 (3)	9 (5)	.005
90-Day mortality	45 (3)	11 (2)	20 (5)	14 (8)	<.001
30-Day readmission <sup>b</sup>	165 (13)	66 (9)	65 (16)	34 (18)	<.001
90-Day readmission <sup>b</sup>	258 (20)	113 (16)	91 (22)	54 (29)	<.001
Long-term outcomes, % (95% CI)					
5-Year OS	44 (41-47)	49 (45-53)	44 (39-49)	28 (21-35)	<.001
10-Year OS	29 (25-33)	35 (30-41)	23 (14-34)	16 (9-24)	<.001
5-Year CSS	46 (43-50)	49 (44-53)	47 (40-53)	35 (27-44)	<.001
10-Year CSS	NA	NA	NA	NA	

**Management and Outcome of Colorectal Cancer Liver Metastases in Elderly Patients: a Population-based Study. C.M, Booth, JAMA | Oncol 2015 | 1(8):1111-1119**

Adjusted cancer-specific survival (CCS)



Age group, y						
≥75	186	95	40	16	<6	0
65-74	414	245	103	36	6	0
<65	710	489	210	82	17	0



“Ai danni del tumore non si può rimediare. L’operazione, come la vedo io, eviterà ulteriori conseguenze \_ a meno che non fosse **l’operazione stessa** a causare una qualche ulteriore conseguenza...ma questo non lo dissi.”

*P. Roth*


1991, Patrimonio. Una storia vera

**Bile Duct Carcinoma in the Elderly. A rationale for Surgical Management. W. Longmire. Arc Surg | 1991 | 126:433-435**

## **What are the key points?**

This study indicates that surgical management of bile duct tumors in elderly patients provides an opportunity for a definitive diagnosis, the best possible patient selection, improved long-term survival, and the only chance for cure. Moreover, bile duct tumors in a population of elderly patients can be managed surgically with relatively low mortality rates. **Therefore, we believe that elderly patients should not be denied surgical evaluation simply on the basis of age.**

**Bile Duct Carcinoma in the Elderly. A rationale for Surgical Management. W. Longmire. Arc Surg | 1991 | 126:433-435**



**Fig 3.**— Comparison of the survival curves for elderly patients with bile duct cancer treated between 1954 and 1978 (group 1, solid line,  $n=20$ ) with those treated between 1979 and 1988 (group 2, broken line,  $n=22$ ). Asterisk indicates  $P<.05$  (group 2 vs group 1).

Patterns of care and treatment outcomes in older patients with biliary tract cancer. *A. Horgan. Oncotarget* | 2015 | 6:44995-45003

## What are the key points?

Early stage disease (stage I/II) and ECOG PS < 2 were associated with surgical intervention and survival outcomes **did not differ between older and younger** patients (median survival 21.1 months in both group). Older patients with BTC are less likely to be offered chemotherapy compared to younger patients. Treatment decisions for BTC in older patients should thus not be guided solely by the biological age of the patient, and **active management** should be considered for this patient population if deemed appropriate following clinical assessment.

Patterns of care and treatment outcomes in older patients with biliary tract cancer. *A. Horgan. Oncotarget | 2015 | 6:44995-45003*




Figure 1 . Overall survival for all patients by treatment group

Patterns of care and treatment outcomes in older patients with biliary tract cancer. *A. Horgan. Oncotarget | 2015 | 6:44995-45003*





Figure 1 . Overall survival by age and treatment group




“Il tumore, in un tempo ragionevolmente breve peggiorerà molto. Se operiamo, la **convalescenza sarà difficile**. Un mese...forse anche due o tre mesi. In altri termini, sarà un inferno.

Si, sarà dura – disse lui – **ma se non si fa niente potrebbe essere ancora più dura.**”

*P. Roth*

1991, Patrimonio. Una storia vera

**PROGNOSIS AND PREDICTIVE FACTORS OF PANCRATIC ADENOCARCINOMA**  
**WHO Classification of Tumours of the Digestive System | 4° Edition, 2010**



**Figure 1. The survival rates for curative resection with PADC confined to the pancreas, for curative resection with PADC <30 mm and the overall survival.**


What is the Effect of Age on Pancreatic Resection?. *T.S. Riall. Adv Surgery* | 2009 | 43:233-249

## The background

Pancreatic cancer disproportionately affects the elderly. The overall annual incidence of pancreatic cancer is approximately 11 cases per 100,000 population and over 80% of pancreatic cancer patients are over the age of 60. The incidence increases sharply with age. Patients 80 and older have an annual incidence of 87.2 cases per 100,000 population. Currently, pancreatic resection is the only **potentially curative option** for patients with pancreatic and other periampullary cancers.

What is the Effect of Age on Pancreatic Resection?. *T.S. Riall. Adv Surgery* | 2009 | 43:233-249


## The results



Survival after pancreatic resection for patients age 70 years or older (n=138) compared with that of patients younger than 70 years of age (n=350, p = 0.03).

What is the Effect of Age on Pancreatic Resection?. *T.S. Riall. Adv Surgery* | 2009 | 43:233-249

## The results



Actuarial survival curves comparing all patients with pancreatic cancer under 80 years of age (n=1022, median survival 18 months, 2-year survival 37.7%) to patients aged 80-89 (n=102, median survival 11 months, 2-year survival 33.0%, P=0.002).

What is the Effect of Age on Pancreatic Resection?. *T.S. Riall. Adv Surgery* | 2009 | 43:233-249

## The application

Patients also need to be aware that surgical resection is the only curative option for pancreatic cancer. In reasonable risk elderly patients the benefit of surgical resection does not decrease with age and these patients **can experience long-term survival** and good quality of life. In fact, once patients over 80 get beyond the two year survival mark without cancer recurrence **their survival parallels** that of their age-matched counterparts.

Elderly patients also need to be aware of the fact that **hospital volume and surgeon experience** significantly impact outcomes.

# Case Reports




**Caso 1.** Ilvana, 1931. 83 anni | HCC  
*complicato*

**03.07.2014:** Resezione epatica SVII  
Shock emorragico intraoperatorio  
Terapia Intensiva

Reparto

**21.07.2014:** DNR h. 17:00 | Decesso: h. 21:00



**Caso 2.** Gilberto, 1934. 83 anni | HCC *vasto*

**12.05.2017:** Resezione epatica SVII-VIII  
Nessuna complicazione intraoperatoria  
Terapia Intensiva


Reparto

**30.05.2017:** Dimissioni

# Case Reports




**Caso 3.** Adele, 1929. 88 anni | Neoplasia fegato  
**19.10.2017:** Resezione epatica SV-VI  
Reparto  
**27.10.2017:** Dimissioni  
Diagnosi: Adenoma pleomorfo metastatico



**Caso 4.** Liliana, 1939. 78 anni | Meta CR  
No CHT | No RFA  
**22.06.2015:** Resezione colica per ADC  
**02.02.2018:** Resezione epatica SV + Colectomia  
Reparto  
**08.02.2018:** Dimissioni

# Case Reports




**Caso 5.** Maurizia, 1940. 78 anni | Neo Colecisti?  
**19.10.2016:** Res. epatica SIV-V + Colec.mia | R1  
Reparto  
**28.10.2016:** Dimissioni  
Diagnosi: ADC Colecisti + M LN + M Peritoneale  
CHT | Libera da ricaduta




**Caso 6.** Pasqua, 1937. 81 anni | ADC Colec | VB  
**12.02.2018:** Colec.mia + Res epatica + Bypass  
BE  
Reparto  
Fistola biliare | Trattamento conservativo  
**22.03.2018:** Trasferimento Medicina Lagosanto  
Tuttora ricoverata in Lungo Degenza Lagosanto


# Qualche Caso Clinico



**Caso 7.** Marisa, 1932. 85 anni |ADC Duodeno  
**13.04.2017:** Duodeno Pancreasectomia Totale  
Terapia Intensiva  
Reparto | Nessuna complicazione  
**10.05.2017:** Dimissione  
**08.08.2017:** Decesso per cause non tumorali



**Caso 8.** Giuseppino, 1939. 78 anni |ADC DB  
**08.02.2018:** Duodeno Pancreasectomia Totale  
Reparto  
Terapia Intensiva per complicazione polmonare  
Reparto  
**15.03.2018:** Trasferimento L. D. Lagosanto




“Senti, ecco come stanno le cose. **Se muore sotto i ferri, bè, sarà morto ad 86 anni, che non è l’età peggiore per morire.** Se sopravvive, e se l’operazione è andata bene, cosa che, come dice il chirurgo, si verifica nel settantacinque per cento dei casi, allora benissimo”.

*P. Roth*

1991, Patrimonio. Una storia vera

# A Conceptual Framework for Appropriateness in Surgical Care

Z. Cooper. | Anesthesiology | 2015



# *Note finali* & Conclusioni

## CHIRURGIA EPATOBILIARE e PANCREATICA

**G. Bettelli, *Perioperative Care of the Elderly***

**2018**

- I pazienti anziani difficilmente sono elegibili a studi clinici randomizzati
- Improbabile attendersi risposte definitive dalla letteratura scientifica
- Accordare la decisione alle volontà del paziente
- Considerare le aspettative prognostiche dei tumori del distretto EBP
- Valutare le probabilità di successo di una procedura complessa EBP
- Calcolare i rischi connessi alla procedura chirurgica
- Calcolare la possibilità e le conseguenze di un insuccesso
- Considerare le implicazioni di negare una chirurgia potenzialmente curativa

**Gray Turner, *Encouragements in Cancer Surgery***

**1925**

Effects of age on survival in patients undergoing resection of hepatocellular carcinoma. *A. Cucchetti, British J Surg | 2016 | 103:93-99*




Fig1. Mean survival difference between patients who underwent resection and the age-, year- and sex-matched reference population after 40 years of extrapolation. The shaded area represents the mean number of years for life lost (YLL) after surgery for the entire study population.